1060-High-Throughput Selection of Fast-Acting Protein Drugs
This research presents a novel high-throughput yeast display platform designed to engineer fast-acting covalent protein drugs that overcome the limitations of rapid systemic clearance. By integrating site-specific chemical crosslinkers with precise protein mutations, the authors successfully developed IB101, a potent PD-L1 antagonist, and IB201, a covalent IL-18 agonist. These engineered proteins achieve rapid target engagement and sustained receptor occupancy, leading to superior antitumor efficacy in vivo compared to traditional non-covalent antibodies. The study further demonstrates the…
The skinny
The skinny isn't ready yet — notes appear once the transcript is processed.